Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pazopanib in unresectable or metastatic malignant peripheral nerve sheath tumor and chemoresistant soft tissue sarcomas
jRCTs041180114Phase 2Completed
- Sponsor
- Japanese Musculoskeletal Oncology Group
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in malignant peripheral nerve sheath tumor (MPNST), alveolar soft part sarcoma (ASPS), epithelioid sarcoma (ES) and 2 more, sponsored by Japanese Musculoskeletal Oncology Group. Primary endpoint: Clinical benefit rate at 12 weeks (RECIST). Started Dec 2016; status: completed.
02
Drugs
pazopanib
03
Conditions
malignant peripheral nerve sheath tumor (MPNST)alveolar soft part sarcoma (ASPS)epithelioid sarcoma (ES)clear cell sarcoma (CCS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on jRCTs041180114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180114.